BMI1 and hypoparathyroidism-retardation-dysmorphism syndrome: These results, paired with the unique relationship of BMI1 abundance with disease outcome in HRP, but not HRD patients, suggest that targeting BMI1 may represent a hitherto unrecognized therapeutic opportunity in HRP proficient HGSOC tumors.